

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

VOLUNTARY ANNOUNCEMENT
LAUNCH OF HEPARIN SODIUM INJECTION IN THE USA

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, together with its subsidiaries referred to as the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that Techdow USA Inc. (“**Techdow USA**”), a subsidiary of the Company mainly engaging in heparin and low molecular weight heparin finished dose business, has commenced operations and launched and formally marketed its heparin sodium injection in the United States.

As the Company is a FDA-approved manufacturer of both heparin active pharmaceutical ingredients (API) and heparin finished dosage form (FDF), the Board believes that Techdow USA, a subsidiary of the Company, will leverage on the Group’s global networks and vertical supply chains to provide stable and reliable heparin products at competitive pricing to the U.S. market and enhance the Group’s penetration in the U.S. market.

This announcement is being made by the Group on a voluntary basis to update its shareholders and potential investors on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, pharmaceutical products or orally consumed product.

Announcement is hereby given.

By Order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
27 January, 2022

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.